+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-10-17Number of Pages: 101

Asthma and COPD Drugs Market (Drug Class - Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs; Indication - Asthma and COPD) - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

U.S. and China Asthma and COPD Drugs Market: Snapshot

The market for asthma and COPD drugs in the U.S. and China is poised to present a steady incremental opportunity in the years to come. A rise in the affected patient pool, an improved diagnosis rate for respiratory diseases, and heightened patient awareness regarding treatment options are identified as the key factors driving this market.

The U.S. and China asthma and COPD drugs market is expected to witness moderate growth in the first half of the forecast period, primarily due to the patent expiry of leading drug brands and price erosion in the market. However, by 2020, novel drugs are expected to enter the asthma and COPD drugs market, which is likely to push the market toward a positive future.

The market is slated to expand at a modest CAGR of 4.1% over the course of the forecast period, rising from a valuation of US$13.0 bn in 2015 to US$18.7 bn by 2024.

us china asthma copd drugs market

Recommendations from Global Bodies Drive Preference for Combination Drugs

Based on drug class, in 2015, combination drugs held a prominent share of over 54% in the U.S. and China asthma and COPD drugs market. The segment is slated to witness high growth during the forecast period, which is attributed to the popularity of and preference for combination drugs. The launch of triple combination therapies currently in pipeline by companies such as Chiesi Pharmaceuticals, GSK, and Circassia is also responsible for the growth of this segment.

Both in the U.S. and China, prescription is more inclined toward combination drugs as guidelines by Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend them as a safer option for the management of asthma and COPD.

An emerging drug class with the potential to create a prominent position in the U.S. and China asthma and COPD drugs market in the coming years is monoclonal antibodies. The launch of new products in this segment is anticipated to bolster its growth during the forecast period.

U.S. Leading Market for Asthma and COPD Drugs; China Most Lucrative

Accounting for a massive 81.4% share in the asthma and COPD drugs market by 2016, the U.S. is the clear leader and will continue its dominance through 2024. This can be primarily attributed to greater awareness among patients and higher prices of asthma and COPD drugs. New product launches, such as FDA-approved Nucala, and a rise in awareness initiatives through apps and educational programs have helped build a strong foundation for treatment in the U.S., making it a profitable country to invest in. Pipeline studies by major players for biologics as well as combination therapies is also a key trend observed over the years. Most prominent companies view the U.S. as a value market, and thus consider it an important part of their new product launch strategy.

In terms of market size, however, the asthma and COPD drugs market in the U.S. is expected to initially decline owing to lower sales triggered by a decrease in revenue from off-patent blockbuster drugs. Nevertheless, new product launches are likely to drive the market from 2021 onward.

Although China accounts for a much smaller share in the U.S. and China asthma and COPD drugs market, it has been identified to be an extremely attractive market, expanding at an impressive CAGR of 10.0% from 2016 to 2024. This is mainly driven by higher unmet medical needs in the country and a rise in the number of asthma patients. The growing incidence of COPD can be attributed to an increase in the number of smokers. A high growth rate, coupled with a low degree of competition in the market compared to the U.S., makes China an attractive investment option for makers of asthma and COPD drugs.

Key companies in the U.S. and China asthma and COPD drugs market include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: U.S. and China Asthma and COPD Drugs Market

Chapter 4. Market Overview
4.1. Introduction 
4.2. Key Industry Developments
4.3. Market Dynamics
      4.3.1. Drivers
      4.3.2. Restraints
      4.3.3. Opportunity
4.4. Porter’s Five Forces Analysis

Chapter 5. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Drug Class
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Drug Class
      5.3.1. Bronchodilators
               5.3.1.1. Short Acting Beta-2 Agonists 
               5.3.1.2. Long Acting Beta-2 Agonists
               5.3.1.3. Anti-cholinergic Agents 
      5.3.2. Anti-inflammatory Drugs
               5.3.2.1. Oral and Inhaled Corticosteroids
               5.3.2.2. Anti-leukotrienes
               5.3.2.3. Phosphodiesterase Type-4 Inhibitors
               5.3.2.4. Others
      5.3.3. Monoclonal Antibodies
      5.3.4. Combination Drugs
5.4. Market Attractiveness Analysis, by Drug Class, 2015
5.5. Key Trends

Chapter 6. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Indication
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Indication
      6.3.1. Asthma
      6.3.2. COPD
6.4. Market Attractiveness Analysis, by Indication, 2015
6.5. Key Trends

Chapter 7. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Region
7.1. Market Scenario
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
      7.3.1. U.S.
      7.3.2. China
7.4. Market Attractiveness Analysis, by Region, 2015

Chapter 8. U.S. Asthma and COPD Drugs Market Analysis and Forecast 
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Drug Class
      8.3.1. Bronchodilators
               8.3.1.1. Short Acting Beta-2 Agonists 
               8.3.1.2. Long Acting Beta-2 Agonists
               8.3.1.3. Anti-cholinergic Agents 
      8.3.2. Anti-inflammatory Drugs
               8.3.2.1. Oral and Inhaled Corticosteroids
               8.3.2.2. Anti-leukotrienes
               8.3.2.3. Phosphodiesterase Type-4 Inhibitors
               8.3.2.4. Others
      8.3.3. Monoclonal Antibodies
      8.3.4. Combination Drugs
8.4. Market Size (US$ Mn) Forecast, by Indication
      8.4.1. Asthma
      8.4.2. COPD
      8.4.3. Canada
8.5. Market Attractiveness Analysis, by Drug Class, 2015
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Key Trends

Chapter 9. China Asthma and COPD Drugs Market Analysis and Forecast 
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Drug Class
      9.3.1. Bronchodilators
               9.3.1.1. Short Acting Beta-2 Agonists 
               9.3.1.2. Long Acting Beta-2 Agonists
               9.3.1.3. Anti-cholinergic Agents 
      9.3.2. Anti-inflammatory Drugs
               9.3.2.1. Oral and Inhaled Corticosteroids
               9.3.2.2. Anti-leukotrienes
               9.3.2.3. Phosphodiesterase Type-4 Inhibitors
               9.3.2.4. Others
      9.3.3. Monoclonal Antibodies
      9.3.4. Combination Drugs
9.4. Market Size (US$ Mn) Forecast, by Indication
      9.4.1. Asthma
      9.4.2. COPD
      9.4.3. Canada
9.5. Market Attractiveness Analysis, by Drug Class, 2015
9.6. Market Attractiveness Analysis, by Indication, 2015
9.7. Key Trends

Chapter 10. Competition Landscape
10.1. Global Asthma and COPD Drugs Market Share Analysis, Key Players, 2015
10.2. Competition Matrix
10.3. Company Profiles
      10.3.1. AstraZeneca plc
               10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.1.2. Financial Overview
               10.3.1.3. Product Portfolio
               10.3.1.4. SWOT Analysis
               10.3.1.5. Strategic Overview
      10.3.2. Boehringer Ingelheim GmbH
               10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.2.2. Financial Overview
               10.3.2.3. Product Portfolio
               10.3.2.4. SWOT Analysis
               10.3.2.5. Strategic Overview
      10.3.3. F Hoffmann-La Roche Ltd.
               10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.3.2. Financial Overview
               10.3.3.3. Product Portfolio
               10.3.3.4. SWOT Analysis
      10.3.4. GlaxoSmithKline plc
               10.3.4.1. Company Overview (HQ, business segments, employee strength)
               10.3.4.2. Financial Overview
               10.3.4.3. Product Portfolio
               10.3.4.4. SWOT Analysis
               10.3.4.5. Strategic Overview
      10.3.5. Merck & Co., Inc.
               10.3.5.1. Company Overview (HQ, business segments, employee strength)
               10.3.5.2. Product Portfolio
               10.3.5.3. SWOT Analysis
               10.3.5.4. Recent Developments
               10.3.5.5. Strategic Overview
      10.3.6. Novartis AG
               10.3.6.1. Company Overview (HQ, business segments, employee strength)
               10.3.6.2. Financial Overview
               10.3.6.3. Product Portfolio
               10.3.6.4. SWOT Analysis
               10.3.6.5. Strategic Overview

List of Figures

Figure 1: U.S. and China Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 2: U.S. and China Asthma and COPD Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 3: U.S. and China Bronchodilators Market Revenue (US$ Mn), 2014–2024
Figure 4: U.S. and China Anti-inflammatory Drugs Market Revenue (US$ Mn), 2014–2024
Figure 5: U.S. and China Monoclonal Antibodies Market Revenue (US$ Mn), 2014–2024
Figure 6: U.S. and China Combination Drugs Market Revenue (US$ Mn), 2014–2024
Figure 7: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Drug Class, 2015
Figure 8: U.S. and China Asthma and COPD Drugs Value Share Analysis, by Indication, 2016 and 2024
Figure 9: U.S. and China Asthma Market Revenue (US$ Mn), 2014–2024
Figure 10: U.S. and China COPD Market Revenue (US$ Mn), 2014–2024
Figure 11: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Indication, 2015
Figure 12: Global U.S. and China Asthma and COPD Drugs Value Share Analysis, by Region, 2016 and 2024
Figure 13: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Region, 2015
Figure 14: U.S. Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 15: U.S. Asthma and COPD Drugs Market Y-o-Y Growth Projections, 2015–2024
Figure 16: U.S. Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 17: U.S. Market Value Share Analysis, by Indication, 2016 and 2024
Figure 18: U.S. Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Drug Class, 2014–2024
Figure 19: U.S. Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Indication, 2014–2024
Figure 20: U.S. Asthma and COPD Drugs Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: U.S. Asthma and COPD Drugs Market Attractiveness Analysis, by Indication, 2015
Figure 22: China Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 23: China Asthma and COPD Drugs Market Y-o-Y Growth Projections, 2015–2024
Figure 24: China Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 25: China Market Value Share Analysis, by Indication, 2016 and 2024
Figure 26: China Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Drug Class, 2014–2024
Figure 27: China Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Indication, 2014–2024
Figure 28: China Asthma and COPD Drugs Market Attractiveness Analysis, by Drug Class, 2015
Figure 29: China Asthma and COPD Drugs Market Attractiveness Analysis, by Indication, 2015
Figure 30: Global Asthma and COPD Drugs Market Share Analysis, by Company (2015)

List of Tables

Table 1: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 2: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication, 2014–2024
Table 3: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Region, 2014–2024
Table 4: U.S. Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 5: U.S. Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication Type, 2014–2024
Table 6: China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 7: China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication, 2014–2024

U.S. and China Asthma and COPD Drugs Market: Overview

Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the WHO predicts that COPD will become the third most common cause of death globally by 2030. However, these statistics have already materialized in the U.S. and China, where COPD is currently said to be the third leading cause of mortality.

According to the Asthma and Allergy Foundation of America, asthma is the leading chronic disease in children in the U.S. It is also the most common reason for missed school days. Moreover, an estimated 10 people in the U.S. die from asthma each day, while 3,630 die each year. In China, the figures are worse. A large population of COPD patients goes underdiagnosed or misdiagnosed in China every year. A large proportion of these deaths are avoidable with proper treatment and care. Thus, the existence of an unmet medical need is clearly evident and is anticipated to augment the asthma and COPD drugs market.

U.S. and China Asthma and COPD Drugs Market: Scope and Methodology

This report on the asthma and COPD drugs market in the U.S. and China analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as technological developments, patent expiry, recent drug approvals, investment in clinical studies and acquisitions by leading players in the market, and historical year-on-year growth have been taken into consideration while estimating the market size.

Growth rates for each segment within the U.S. and China asthma and COPD drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, drug development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the asthma and COPD drugs market in the U.S and China.

U.S. and China Asthma and COPD Drugs Market: Segmentation

Based on drug class, the asthma and COPD drugs market in the U.S and China has been segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. The bronchodilator class has been further segmented into short acting beta-2 agonists, long acting beta-2 agonists, and anti-cholinergic agents. The anti-inflammatory drug class has been further segmented into oral and inhaled corticosteroids, anti-leukotrienes, phosphodiesterase type 4 inhibitors, and others. The others segment includes mast cell stabilizers and other anti-inflammatory agents used in asthma and COPD control.

Based on indication, the asthma and COPD drugs market in the U.S. and China has been segmented into asthma and COPD. According to the CDC, one in 12 people in the U.S. has asthma, and the number is rising each year. Pollution in China is among the worst in the world. This is likely to worsen asthma and COPD symptoms, consequently driving the asthma and COPD market in China during the forecast period.

Geographically, the asthma and COPD market has been segmented into two countries: the U.S. and China. These countries have been further segmented by indication and drug class.

U.S. and China Asthma and COPD Drugs Market: Competitive Landscape

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the asthma and COPD drugs market in the U.S. and China. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

The U.S. and China asthma and COPD drugs market has been segmented as follows:

U.S. and China Asthma and COPD Drugs Market, by Drug Class

  • Bronchodilators 
    • Short Acting Beta-2 Agonists
    • Long Acting Beta-2 Agonists
    • Anti-cholinergic Agents 
  • Anti-inflammatory Drugs 
    • Oral and Inhaled Corticosteroids
    • Anti-leukotrienes
    • Phosphodiesterase Type-4 Inhibitors
    • Others 
  • Monoclonal Antibodies
  • Combination Drugs

U.S. and China Asthma and COPD Drugs Market, by Indication

  • Asthma
  • COPD


 
 
Back To Top